| Atrial Fibrillation Management and Outcomes | Lifetime | 44 | DK 1 | 99.83 |
| Heart Failure Treatment and Management | Lifetime | 56 | DK 2 | 99.76 |
| Cardiovascular Function and Risk Factors | Lifetime | 132 | DK 2 | 99.73 |
| Cardiac electrophysiology and arrhythmias | Lifetime | 107 | DK 1 | 99.61 |
| Cardiac Arrest and Resuscitation | Lifetime | 143 | DK 2 | 99.45 |
| Cardiac pacing and defibrillation studies | Lifetime | 99 | DK 3 | 99.61 |
| Antiplatelet Therapy and Cardiovascular Diseases | Lifetime | 84 | DK 4 | 99.52 |
| Blood Pressure and Hypertension Studies | Lifetime | 145 | DK 1 | 99.46 |
| Cardiac Arrhythmias and Treatments | Lifetime | 191 | DK 2 | 99.43 |
| Venous Thromboembolism Diagnosis and Management | Lifetime | 252 | DK 6 | 99.22 |
| Acute Myocardial Infarction Research | Lifetime | 251 | DK 5 | 99.16 |
| COVID-19 and healthcare impacts | Lifetime | 230 | DK 1 | 96.61 |
| Cardiac, Anesthesia and Surgical Outcomes | Lifetime | 675 | DK 13 | 98.62 |
| Heart Rate Variability and Autonomic Control | Lifetime | 407 | DK 9 | 98.58 |
| Diabetes Treatment and Management | Lifetime | 363 | DK 18 | 98.64 |
| Cardiac Health and Mental Health | Lifetime | 251 | DK 4 | 98.05 |
| Infective Endocarditis Diagnosis and Management | Lifetime | 537 | DK 5 | 97.97 |
| Cardiovascular Syncope and Autonomic Disorders | Lifetime | 301 | DK 8 | 97.11 |
| Mechanical Circulatory Support Devices | Lifetime | 730 | DK 10 | 97.26 |
| Cardiovascular Health and Disease Prevention | Lifetime | 806 | DK 10 | 96.66 |
| Inflammatory mediators and NSAID effects | Lifetime | 805 | DK 19 | 95.92 |
| Potassium and Related Disorders | Lifetime | 194 | DK 4 | 96.35 |
| Pharmacology and Obesity Treatment | Lifetime | 530 | DK 11 | 94.65 |
| Disaster Response and Management | Lifetime | 795 | DK 5 | 93.16 |
| Healthcare Technology and Patient Monitoring | Lifetime | 554 | DK 8 | 86.17 |
| Heart rate and cardiovascular health | Lifetime | 466 | DK 7 | 77.01 |
| Cardiac Arrest and Resuscitation | 2021-2025 | 94 | DK 11 | 98.74 |
| Antiplatelet Therapy and Cardiovascular Diseases | 2021-2025 | 148 | DK 2 | 96.60 |
| Acute Myocardial Infarction Research | 2021-2025 | 298 | DK 5 | 96.09 |
| COVID-19 and healthcare impacts | 2021-2025 | 529 | DK 2 | 92.66 |
| Cardiovascular Function and Risk Factors | 2021-2025 | 623 | DK 13 | 95.98 |
| Trauma and Emergency Care Studies | 2021-2025 | 335 | DK 6 | 93.43 |
| Cardiac Health and Mental Health | 2021-2025 | 256 | DK 10 | 92.63 |
| Emergency and Acute Care Studies | 2021-2025 | 353 | DK 9 | 92.12 |
| Venous Thromboembolism Diagnosis and Management | 2021-2025 | 630 | DK 11 | 93.82 |
| Atrial Fibrillation Management and Outcomes | 2021-2025 | 863 | DK 24 | 94.32 |
| Diabetes Treatment and Management | 2021-2025 | 585 | DK 17 | 94.03 |
| Heart Failure Treatment and Management | 2021-2025 | 524 | DK 8 | 93.67 |
| Mechanical Circulatory Support Devices | 2021-2025 | 641 | DK 15 | 92.90 |
| Reproductive Health and Contraception | 2021-2025 | 237 | DK 2 | 89.05 |
| Blood Pressure and Hypertension Studies | 2021-2025 | 954 | DK 2 | 88.02 |
| Estrogen and related hormone effects | 2021-2025 | 306 | DK 6 | 84.95 |
| Disaster Response and Management | 2021-2025 | 355 | DK 9 | 85.31 |
| Cardiovascular Effects of Exercise | 2021-2025 | 691 | DK 10 | 85.57 |
| Cardiovascular Issues in Pregnancy | 2021-2025 | 620 | DK 4 | 79.62 |
| Electrolyte and hormonal disorders | 2021-2025 | 339 | DK 11 | 78.49 |
| Healthcare cost, quality, practices | 2021-2025 | 650 | DK 6 | 75.32 |
| Cardiovascular Syncope and Autonomic Disorders | 2021-2025 | 596 | DK 14 | 72.98 |
| Medication Adherence and Compliance | 2021-2025 | 730 | DK 4 | 72.85 |
| Menopause: Health Impacts and Treatments | 2021-2025 | 407 | DK 4 | 67.31 |
| Phytoestrogen effects and research | 2021-2025 | 437 | DK 5 | 63.94 |
| Potassium and Related Disorders | 2021-2025 | 639 | DK 12 | 62.98 |
| Intramuscular injections and effects | 2021-2025 | 160 | DK 3 | 63.06 |
| Healthcare Technology and Patient Monitoring | 2021-2025 | 382 | DK 13 | 57.51 |
| Otitis Media and Relapsing Polychondritis | 2021-2025 | 713 | DK 17 | 56.77 |
| Takotsubo Cardiomyopathy and Associated Phenomena | 2021-2025 | 854 | DK 7 | 39.87 |